Schedule 13G ownership disclosure

AN2 Therapeutics, Inc.

Common Stock, $0.00001 par value per share · CUSIP: 037326105

Event date: 2024-12-31

Filing-level shares
5,749,432
Percent of class
19.2%
  • BML Investment Partners, L.P.

    Shares: 5,749,432 · Class: 19.2%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001373604-25-000020
Form type
SCHEDULE 13G/A
Filer
AN2 Therapeutics, Inc.
CIK
CIK 1880438
Filed
Feb 13, 2025
Reporting period
Dec 31, 2024
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub